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Abstract
Reducing dietary fat intake and excess adiposity, the cornerstones of behavioral treatment of insulin resistance(IR), are
marginally successful over the long term. Ad36, a human adenovirus, offers a template to improve IR, independent of
dietary fat intake or adiposity. Ad36 increases cellular glucose uptake via a Ras-mediated activation of phosphatidyl inositol
3-kinase(PI3K), and improves hyperglycemia in mice, despite a high-fat diet and without reducing adiposity. Ex-vivo studies
suggest that Ad36 improves hyperglycemia in mice by increasing glucose uptake by adipose tissue and skeletal muscle, and
by reducing hepatic glucose output. It is impractical to use Ad36 for therapeutic action. Instead, we investigated if the
E4orf1 protein of Ad36, mediates its anti-hyperglycemic action. Such a candidate protein may offer an attractive template
for therapeutic development. Experiment-1 determined that Ad36 ‘requires’ E4orf1 protein to up-regulate cellular glucose
uptake. Ad36 significantly increased glucose uptake in 3T3-L1 preadipocytes, which was abrogated by knocking down
E4orf1 with siRNA. Experiment-2 identified E4orf1 as ‘sufficient’ to up-regulate glucose uptake. 3T3-L1 cells that inducibly
express E4orf1, increased glucose uptake in an induction-dependent manner, compared to null vector control cells. E4orf1
up-regulated PI3K pathway and increased abundance of Ras–the obligatory molecule in Ad36-induced glucose uptake.
Experiment-3: Signaling studies of cells transiently transfected with E4orf1 or a null vector, revealed that E4orf1 may activate
Ras/PI3K pathway by binding to Drosophila discs-large(Dlg1) protein. E4orf1 activated total Ras and, particularly the H-Ras
isoform. By mutating the PDZ domain binding motif(PBM) of E4orf1, Experiment-4 showed that E4orf1 requires its PBM to
increase Ras activation or glucose uptake. Experiment-5: In-vitro, a transient transfection by E4orf1 significantly increased
glucose uptake in preadipocytes, adipocytes, or myoblasts, and reduced glucose output by hepatocytes. Thus, the highly
attractive anti-hyperglycemic effect of Ad36 is mirrored by E4orf1 protein, which may offer a novel ligand to develop anti-
hyperglycemic drugs.
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Introduction
The United States alone has about 26 million individuals with
diabetes mellitus (DM), and even more (79 million) with
prediabetes (PreDM) (National Diabetes Factsheet released by
the Centers for Disease Control http://www.cdc.gov/diabetes/
pubs/pdf/ndfs_2011.pdf). Better drugs are urgently needed to
treat hyperglycemia and associated comorbidities. Most anti-
diabetic agents yield better results, if combined with behavior
modification to reduce dietary fat intake and obesity. However,
despite their obvious health benefits, long term compliance with
such behavioral changes is highly challenging for the general
population. Therefore, agents to improve insulin resistance
independent of adiposity or dietary fat intake would be extremely
attractive and of practical benefit.
Our recent data indicate that Ad36, a human adenovirus, may
offer a template to develop such an agent. In humans, natural
Ad36 infection predicts better glycemic control independent of
age, sex or adiposity [1]. Experimental Ad36 infection of mice
improves hyperglycemia, despite a 60% fat diet and without
reducing adiposity [1]. Signaling studies suggest that in these mice,
Ad36 improves glycemic control by increasing glucose uptake by
adipose tissue and skeletal muscle and by reducing hepatic glucose
output [1]. Mechanistic in vitro studies show that Ad36 increases
insulin independent glucose uptake in diabetic and non-diabetic
human adipose tissue explants [2] and in human primary muscle
cell culture in a dose dependent manner [3]. Ad36 requires Ras
mediated activation of phosphatidyl inositol 3-kinase (PI3K), to
increase cellular glucose uptake [2,3].
Collectively, these data reveal anti-hyperglycemic properties of
Ad36,that are clinically relevant to humans, and offer a tool to
develop new anti-diabetic agents. Harnessing certain properties of
viruses for beneficial purposes has been creatively used for several
years. For example, anti-bacterial properties of bacteriophage
virus [4], the oncolytic ability of a mutant adenovirus [5], or the
use of Herpes simplex virus and several other viruses for lysing
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drugs [7,8]. Clearly, infection with Ad36 is not a viable treatment
option. Instead, identifying the viral protein responsible for Ad36-
induced glucose disposal is the next step in harnessing the anti-
hyperglycemic potential of the virus for therapeutic purpose.
Adenoviruses have a set of several early genes that encode
proteins for evading the host immune system and changing cell
function for favorable viral replication, and several late genes, that
encode structural proteins required for viral particle assembly.
This study identified the Ad36 gene that mediates the glucose
disposal induced by the virus. Considering that Ad36 requires
Ras/PI3K pathway for enhancing glucose uptake [2,3], we
focused on E4orf1 gene of the virus that up-regulates this pathway
[9]. The E4orf1 gene of Ad36 is transcribed from the first open
reading frame of Ad36 early gene 4, and yields a 17 kDa, 125
amino acid protein, and has a PBM through which it interacts with
other proteins containing PDZ regions for scaffolding [9]. E4orf1
is necessary and sufficient for Ad36 to activate the PI3K pathway
[9], and its PBM is required for the effect. E4orf1 protein of Ad9, a
closely related adenovirus, stimulates Ras-mediated PI3K activa-
tion [10,11], via the interaction of its PBM with Dlg1 protein. In
Ad36 infected animals, E4orf1 is expressed in adipose tissue or
livers [1,12], and its expression in the liver positively correlates
with glycemic improvement in mice [1]. This background
provided the rationale to test the role of E4orf1 as the mediator
of Ad36-induced glucose uptake, as outlined below.
By knocking down E4orf1 gene expression in Ad36-infected
cells, Experiment 1 determined that Ad36 ‘requires’ its E4orf1
protein for up-regulating cellular glucose uptake. Next, by
inducibly expressing only E4orf1 in cells, Experiment 2 identified
E4orf1 as ‘sufficient’ to up-regulate the Ras pathway and glucose
uptake. Experiment 3 revealed that similar to the action of E4orf1
of Ad9, Ad36 E4orf1 may activate Ras by binding to Dlg1 protein.
Moreover, total Ras and particularly, the H-Ras isoform is
significantly increased and activated by Ad36 E4orf1. By mutating
the PBM of Ad36 E4orf1, Experiment 4 showed that E4orf1
requires its PBM to activate Ras or to increase glucose uptake.
Finally, Experiment 5 determined that transient transfection by
E4orf1 significantly increases glucose uptake in preadipocytes,
adipocytes, and myoblasts, and significantly reduces glucose
output by hepatocytes.
Methods
Outline of each experiment is described below, followed by a
detailed description of the techniques and assays (T&A) used. We
employed multiple approaches, including siRNA knockdown of
Ad36 E4orf1, transient or stable transfection of cells with E4orf1,
or constitutive expression of E4orf1 or its mutant, to test the role of
E4orf1 in glucose uptake. To pull down proteins, or to test the
response of different cell types, V-5 tagged E4orf1 plasmid
transfection was used. To obtain large amount of protein required
to determine the activation of Ras and its isoforms, a preadipocyte
cell line with stable, inducible expression of E4orf1 was used.
Finally, cells that constitutively express E4orf1 were used to
confirm if glucose uptake is attributed to intact E4orf1 and
abrogated by mutating the protein. Specific experiments are
described below.
Experiment 1: Does Ad36 ‘require’ E4orf1 for glucose
uptake?
3T3-L1 preadipocytes were plated in 12-well plates and
transfected the next day using Lipofectamine (2 mL/well) (Invitro-
gen, #18324-012) with 100 pmol of either E4orf1 siRNA
(Ambion #AM16100) or non-targeting (NT) siRNA (Thermo
Scientific, #D-001810-02-05). Immediately upon transfection, the
E4orf1 siRNA transfected cells were infected with Ad36 (5 PFU
per cell) or mock infected with media. The NT siRNA transfected
cells were infected with Ad36. Mock-infected cells with E4orf1
siRNA served as a baseline control, and Ad36 infected cells with
either NT siRNA, or with E4orf1 siRNA were the two
experimental groups. Two-days post transfection/infection, basal
2-Deoxy-D-glucose (2DG) uptake was determined as described in
T&A. This experiment was repeated three times with statistically
significant results. Representative data are presented.
Experiment 2: Is E4orf1 ‘sufficient’ to up-regulate cellular
glucose uptake? Does E4orf1 up-regulate the Ras
pathway?
A 3T3-L1 cell line that stably expresses E4orf1 in response to
doxycycline induction was developed as described in T&A. A
TetOn system was used to clone in either pTRE-TIGHT (Null
vector control; pTRE cells) or pTRE-E4orf1-TIGHT (3T3-E4
cells). Basal 2DG uptake was determined 24 h post induction in
the presence of increasing doses of doxycycline (Clonetech,
#631311). Protein was harvested for determining Ras, AKT
phosphorylation (as an indicator of PI3K activation), and the
abundance of Glut4, Glut1 and adiponectin, by WB.
Experiment 3: Does E4orf1 interact with Dlg1 and
activate Ras?
E4orf1 interaction with Dlg1. HEK293 cells were co-
transfected with plasmid expressing Dlg1 (GW1-CMV-HA-Dlg1)
and either one expressing E4orf1 (pcDNA-V5-Ad36 E4orf1) or a
control plasmid (pcDNA-V5-DEST) (Invitrogen #12489-019).
Two days post transfection, protein was harvested and immuno-
precipitated with HA-antibody (Santa Cruz, #sc-7392). E4orf1
was detected using WB with anti-V5 antibody (Invitogen #46-
0705) following the pull down.
Activation of total and isoform-specific Ras. To
determine isoform-specific activation of Ras, the 3T3-E4 and
Null pTRE inducible stable cell lines were induced for 24 hours
with 1,000 ng/mL doxycycline, and the activation was detected
via a pull down assay for the Ras binding domain (RBD) of Raf,
and detected by WB with total and isoform specific antibodies
against H-Ras, N-Ras or K-Ras.
Experiment 4: Does E4orf1 require its PBM for glucose
uptake and Ras activation?
Ras activation. 3T3-L1 cells were transfected with V-5
tagged plasmids expressing intact E4orf1 (pcDNA-V5-Ad36
E4orf1), plasmid expressing E4orf1 with a mutated PBM (Ad36
E4orf-1DPBM-V5-pcDNA) or a null vector (pcDNA-V5-DEST).
Protein was harvested two days post transfection for the detection
of activated Ras via a pull down assay for the Ras binding domain
(RBD) of Raf, and detected by WB.
Glucose uptake. 3T3-L1 cells that constitutively express
Ad36 E4orf1 or a mutated E4orf1 (deleted PBM; DPBM) were
generated as previously described [9], plated on 12-well plates,
and basal 2DG uptake was determined as described in T&A.
Experiment 5: Does E4orf1 modulate glucose disposal in
preadipocytes, adipocytes, myoblasts or hepatocytes?
In separate experiments, 3T3-L1 preadipocytes or adipocytes,
C2C12 myoblasts or HepG2 hepatocytes were transfected with V-
5 tagged plasmids expressing E4orf1 (pcDNA-V5-AD36-E4orf1)
or a null vector (pcDNA-V5-DEST) as described below.
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in 12-well plates and transfected the next day. Two days post
transfection, basal and insulin (100 nM) stimulated 2DG uptake
was determined as described in T&A.
3T3-L1 adipocytes. 3T3-L1 preadipocytes were differen-
tiated as described in T&A for 6 days. The differentiated
adipocytes were transfected by electroporation. Two-days post
transfection, basal or insulin (100 nM) stimulated 2DG uptake was
determined as described in T&A.
C2C12 myoblasts. C2C12 cells were transfected by electro-
poration, and two-days post transfection, basal or insulin (100 nm)
stimulated 2DG uptake was determined as described in T&A.
HepG2 hepatocytes. HepG2 cells were transfected using the
AMAXA nucleofector device (Lonza, #610-10-1) and plated in
96-well plates. Forty hours post-transfection, cells were switched to
serum free medium for 5 hours. Next, they were exposed to serum
free-glucose free media (Invitrogen, #11966) with 0 or 10 nM
insulin for 4 hours. Glucose concentration in the media was
determined using a glucose oxidase assay (Raichem, #R80038).
Glucose values were adjusted to protein concentration as
measured by bicinchoninic-acid assay (BCA) (Sigma Aldrich #
B9643, #C2284) after solubilization of cells with 0.05% sodium
dodecyl sulfate (SDS).
Techniques and Assays
A. Cell Culture. Maintenance media: 3T3-L1 cells were
obtained from American Type Culture Collection (ATCC #CCL-
92-1, Mannassas, VA) and maintained in high glucose Dulbecco’s
Modified Eagle Medium (DMEM) (Invitrogen, #11995), 10%
normal calf serum (#SH30072.03, Hyclone) and an antibiotic-
antimyotic agent (1%) (Sigma Aldrich #A5955). 3T3-L1 E4orf1
clone was maintained in Tet-free fetal bovine serum (Clonetech,
#631101) with 0.25 mg/mL puromycin and 0.05 mg/mL hygro-
mycin (Invitrogen, #10687-010).
Adipogenic differentiation: Two days post confluence, 3T3-L1
preadipocytes plated in 10 cm dishes were induced to differentiate
by adding DMEM containing 10% FBS (#SH30071.03, Lot:
ASL30786, Hyclone), 20 ng/mL insulin, 115 ng/mL isobutyl-
methylxanthine, and 0.39 ng/mL dexamethasone. Forty-eight
hours after the induction, cells were switched to maintenance
media of DMEM containing 10% FBS, and 5 ng/mL insulin.
C2C12 myoblasts were obtained from Dr. Kenneth Eilertsen at
the Pennington Biomedical Research Center, LA. Cells were
maintained in DMEM, 10% fetal calf serum, and an antibiotic-
antimycotic agent (1%).
HepG2 cells were obtained from Dr. Jianping Ye at the
Pennington Biomedical Research Center, LA. They were
maintained in DMEM, 10% fetal calf serum, and an antibiotic-
antimycotic agent (1%).
B. Virus preparation. Ad36 was obtained from American
Type Culture Collection (ATCC # VR-913) and propagated in
A549 cells after plaque purifying three times as described [13,14].
Viral titers were determined by plaque assay and cell inoculations
were expressed as plaque forming units (PFU) per cell [13,14].
C. siRNA Transfection. 3T3-L1 preadipocytes were plated
into 12-well plates (80,000 cells/well) and transfected the next day
with Lipofectamine 2000. A ratio of 2 mL lipofecatmine and
100 pmol Ad36 E4orf1 siRNA or NT siRNA was used for
transfection, which produced 60% knockdown of E4orf1
expression. Knockdown was confirmed two days post
transfection by harvesting RNA and detecting E4orf1 mRNA
via quantitative real time PCR. The following E4orf1 siRNA
sequence was custom designed by Ambion:
Sense siRNA Strand (59R39): GAGAGUGAUUUUUCCUU-
CATT
Antisense siRNA Strand (59R39): UGAAGGAAAAAUCACU-
CUCTC
D. Creation of stable E4orf1 inducible cell line. TetOn
Advanced system (Clonetech, #630930) was used to create a stable
inducible E4orf1 expressing cell line. Early passage 3T3-L1 cells
were co-transfected with the TetON plasmid and a linear
puromycin marker (Clonetech #ST0207), and stable transfectants
were selected using 1 mg/mL puromycin. Selected clones were
screened for TetON integration using transient transfection of p-
Luc-TIGHT. A luciferase assay (Promega, #E1501) was conducted
following doxycycline treatment to identify the clone with the
highest luciferase expression. That clone was then co-transfected
with a linear hygromycin marker (Clonetech, #ST0206) and the
gene of interest plasmid, either pTRE-TIGHT (null vector control)
or pTRE-E4orf1-TIGHT, and double stable transfectants were
selected with a maintenance dose of 0.25 mg/mL puromycin and a
selection dose of 0.1 mg/mL hygromycin. After 15 days selection,
several clones were screened for E4orf1 expression at different doses
and timepoints post doxycycline treatment. RNA was harvested 16,
24, and 48 hours post treatment with 0, 500, 750, and 1,000 ng/ml
doxycycline. E4orf1 expression levels were detected via quantitative
real time PCR. The optimal dose and time point with maximal
E4orf1 expression was determined as 1,000 ng/mL doxycycline, at
24 hours post treatment.
E. Western Blotting. For all WB involving Ad36 E4orf-1-
V5-pcDNA or pcDNA-V5-DEST transfection, cells were
harvested 2 days post transfection in RIPA buffer with protease
and phosphotase inhibitors. Protein concentration was determined
with a BCA assay. SDS-PAGE was performed and proteins were
transferred to PVDF membrane. Twenty mg protein was loaded in
a 7% gel for detection of Glut4 with monoclonal antibody (R&D
Systems # MAB1262) at 1:1000 dilution. Fifteen mg protein was
loaded in to a 10% gel for determination of Ras (Cell Signaling
#3965S) at 1:1000 dilution. To confirm successful transfection of
V5-tagged E4orf-1, V5 antibodies were used at 1:1000 dilution.
Ten percent gels were loaded with 15 mg protein and probed for p-
AKT and total AKT (1:1000) (Cell Signaling #’s 9271 and 9272,
respectively). For detection of Glut 1, 7.5% gels were loaded with
30 mg protein and probed with 1:200 dilution of Glut1 antibody
(Santa Cruz Biotechnologies, # sc-1605). Adiponectin was
detected using 1:1,000 dilution of antibody (Millipore #
MAB3608) after 15 mg protein was loaded in 15% gel. A 1:1000
dilution of beta tubulin antibody (Santa Cruz Biotechnologies, #
sc-9104) was used after Ras activation assay for housekeeping. For
all other proteins, b-actin was used as a loading control (Santa
Cruz # sc-69879)(1:500 dilution). Densitometry was conducted
using Image J software by the National Institutes of Health, and all
graphs are represented as the ratio of the protein of interest to b-
actin.
F. Ras activation assay. 3T3-L1 preadipocytes were
transfected with Ad36 E4orf-1-V5-pcDNA, Ad36 E4orf-1DPBM-
V5-pcDNA or pcDNA-V5-DEST using a 3:1 ratio of
Lipofectamine to plasmid DNA, and harvested two days post
transfection for the Ras activation assay. Ras Activation Kit (#17-
218, Upstate) was used according to manufacturer’s protocol.
After pull-down, 3% of the total whole cell lysate and the slurry
was loaded to a 15% gel, and subjected to SDS-PAGE. After
transfer to PVDF membrane, the Anti-RAS CLONE10 antibody
provided with the Upstate kit was used to detect activated Ras at
the suggested dilution. Using NIH Image J, total Ras was
normalized to b-actin expression, and the ratio of activated to
normalized total Ras is presented in the figures.
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the 3T3-E4 inducible clone and pTRE empty vector clone were
induced with 1,000 ng/mL doxycycline for 24 hours. After the
Ras activation assay (#17-218, Upstate), four separate gels were
loaded with 6% of the whole cell lysate for determination of total
Ras and the slurry for determination of activated Ras. Each WB
was probed with either 1:200 dilution of H-, N-, or K-Ras
antibodies (Santa Cruz # sc-520, sc-519, and sc-30, respectively)
for the detection of each isoform, or the Anti-RAS CLONE10
antibody for determination of total Ras activation. Using NIH
Image J, total Ras was normalized to b-actin expression, and the
ratio of activated to normalized total Ras is presented in the
figures.
G. Dlg1/E4orf1 interaction. HEK 293 cells were co-
transfected with plasmid expressing Dlg1 (GW1-CMV-HA-Dlg1
provided by Dr. Ronald Javier, Baylor College of Medicine,
Houston, TX) and either one expressing E4orf1 (pcDNA-V5-
Ad36 E4orf1) or a control plasmid (pcDNA-V5-DEST)
(Invitrogen #12489-019). Cells were harvested 48 hours later
and lysed in buffer containing Tris-HCl 50 mM pH 7.5, 1%
Triton X-100 150 mM NaCl and complete anti-protease (Sigma
Aldrich, #P8340) anti phosphatase inhibitor cocktail (Thermo
Scientific #78420). One mg of total protein was used to
immunoprecipitate Dlg1 with 5 mg of anti-HA antibodies (Santa
Cruz, #sc-7392). Immonoprecipitated protein complexes were
extensively washed and loaded on SDS-PAGE gel. Membranes
were probed with anti-HA and anti-V5 antibodies (Invitrogen,
#46-0705; 1:1000).
H. Plasmid Preparation and Transfection. The plasmid
pcDNA-V5-E4orf1 was cloned using Invitrogen GateWay system
that included two steps. 1) Direct TOPO cloning of Ad36 E4orf1
cDNA and Ad36 E4orf1DPBM into pENTR-D TOPO vector
(Invitrogen #K2400-20) according to manufacturer’s manuals. 2)
pENTR-E4orf1 vectors from first step was used for recombination
with pcDNA-V5 vector (Invitrogen #12489-019) using LR
Clonase enzyme (Invitrogen # 11791-019) to obtain pcDNA-
V5-E4orf1 which was used for cell transfection.
3T3-L1 preadipocytes were transfected with Lipofectamine
(Invitrogen #18324-012). Cells were plated into 12 well plates
(80,000 cells/well), and transfected the next day with a 3:1 ratio of
lipofectamine to plasmid DNA according to the manufacturer’s
instructions. Transfection was verified via protein harvest and WB
for the detection of V5- tagged E4orf1 with V5 antibodies.
3T3-L1 adipocytes were transfected on day 6 post adipogenic
induction. After trypsinizing with 0.25% trypsin, cells were
counted and transfected by electroporation with AMAXA kit
nucleofection solution L (Lonza, #VCA-1005) according to the
manufacturer’s protocol except that each cuvette contained 2.5
million cells and was plated to two wells of a 12 well plate. The
next day after the cells had settled on the plate, media was gently
removed and replaced with fresh media to remove any remaining
transfection solution and the cells that did not survive transfection.
Transfection was verified via protein harvest and WB for the
detection of V5- tagged E4orf1 with V5 antibodies.
HepG2 cells were transfected using the AMAXA nucleofector
device, Cell Line Nucleofector Kit V (Lonza #VACA-1003) with
either pcDNA-V5-Ad36-E4orf1 or pcDNA-V5-DEST plasmids
and plated in 96-well plates. Nearly confluent HepG2 cells were
trypsinized, counted, and 2 mg of plasmid and 2 million cells were
used per cuvette. Nucleofector program T-028 was used for
transfection, and after resuspension 40,000 cells per well were
plated on 96-well plates for the glucose output assay. Transfection
was verified via protein harvest and WB for the detection of V5-
tagged E4orf1 with V5 antibodies. Glucose output in media was
determined using a glucose oxidase assay (Raichem #R80038)
and normalized to protein content for each well, which was
determined by BCA.
I. Quantitative real-time PCR. E4orf1 was detected using
quantitative real time PCR (qRT-PCR). RNA was harvested and
isolated using a RNA Mini Easy Kit (Qiagen, #74104), and
cDNA was synthesized via RT PCR (Applied Biosystems #
4368814) according to manufacturer’s instructions. An Ad36
E4orf1 FAM nonflourescent primer-probe was custom designed
and synthesized (Integrated DNA Technologies). The E4orf1
primer probe combination is as follows:
Probe 59-/56-FAM/TGC TGC TCT/ZEN/TTA ACC ACA
CGG ACC G/3IABkFQ/-39
Primer 1 59-CCC TCG CGG ACATAC AAA A-39
Primer 2 59-GCC GGG AGA AGA CAT GAT CTC-39
One hundred ng of cDNA was loaded per well in duplicate for
detection of E4orf1. GAPDH (glyceraldehyde phosphate dehy-
drogenase) primer probe was used as a housekeeping gene
(Applied Biosystems, assay ID# Mm99999915_g1), and 2 ng
per well was loaded in duplicate for each sample. Taqman
Universal PCR Mix was used for both genes according to
manufacturer’s instructions (Applied Biosystems #4304437).
Expression was detected with the Applied Biosystems 7900
Sequence Detection System and the DDCt method.
J. Glucose uptake. Cells in 12 well plates were serum starved
for 2 hours, and then washed 26 with PBS before adding 450 mL
K R P( 1 3 6 m MN a C l ,4 . 7 m MK C l ,1 0 m MN a P O 4 ,0 . 9 m M
CaCl2, 0.9 mM MgSO4) with or without 100 nM insulin (Sigma
Aldrich, #15500), depending on the experiment, for 15 minutes. Two
to three wells were treated with KRP plus 100 nM cytochalasin (Sigma
Aldrich, #C6762) for subtraction of nonspecific glucose uptake. Fifty
mLo f1 0 6isotope solution was then added to each well for a final
concentration of 100 nM cold 2-deoxy glucose and 0.5 mCi/mL [3H]-
2-Deoxyglucose (PerkinElmer #NEC720A250UC) for 5 minutes.
Immediately after the 5 minute incubation, cells were washed in ice-
cold PBS. 500 mL of 0.05% SDS was then added to each well, and
after incubation of cells for 30 min at 37uC, 450 mL of cell lysate was
added to a scintillation vial and the remaining 50 mLw a su s e df o r
protein determination via BCA assay. Samples were read on a
Beckman scintillation counter the following day and readings were
normalized to protein content of each well.
Statistical Analyses
The experiment to knock down E4orf1 with siRNA was
repeated three times. Experiments to determine 2DG uptake in
3T3-L1 adipocytes and glucose output in HepG2 cells following
E4orf1 transfection were repeated twice. All assays were
performed with a minimum of three biological replicates. For all
metabolic assays, 8–12 biological replicates were used, and
normalized to protein content. For WB assays, three biological
replicates were used, and using densitometry, the expression of
protein of interest was normalized to a housekeeping protein.
Normalized protein values were compared between groups. AKT
phosphorylation is presented as a ratio of p-AKT to total AKT.
Activated Ras is presented as a ratio of activated Ras to total Ras
normalized to b-actin. Group means were compared to test the
hypotheses, by using a one-way Student’s t-test. Significance was
considered at p,0.05.
Results
Experiment 1: Ad36 ‘requires’ E4orf1 for glucose uptake
To establish E4orf1 as a candidate protein for glucose uptake,
we first investigated if Ad36 requires E4orf1 for glucose uptake, by
Glucose Disposal by E4orf1
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siRNA, knocked down the expression of E4orf1 mRNA by 60% in
Ad36 infected cells, as determined by real time qRT-PCR (data
not shown). Predictably, cells infected with Ad36 and transfected
with NT RNA, increased 2DG uptake by nearly 2.5 fold
compared to mock infected cells transfected with E4orf1 siRNA
(p=0.007; Figure 1). A knockdown of E4orf1 with siRNA
(Ad36+E4orf1 siRNA group) almost entirely abrogated the effect
of Ad36 on 2DG uptake (Figure 1), indicating that E4orf1 is
essential for Ad36 to increase glucose uptake.
Experiment 2: E4orf1 is ‘sufficient’ to up-regulate cellular
glucose uptake. Also, E4orf1 up-regulate the Ras
pathway
3T3-L1 cells that inducibly and stably express Ad36 E4orf1
(3T3-E4 cells) when treated with different doses of doxycylcine
(500, 750, or 1,000 ng/ml), induced different expression levels of
E4orf1 as determined by qRT-PCR (data not shown). 2DG uptake
was nearly identical in pTRE cells with or without exposure to
1000 ng/mL doxycycline (Figure 2A). However, compared to
pTRE cells, exposure to doxycline dose-dependently induced 2DG
uptake in 3T3-E4 cells (Figure 2A). Compared to pTRE cells,
3T3-E4 cells treated with 750 and 1,000 ng/mL increased glucose
uptake by 1.5 and 2.5 fold, respectively. Proteins harvested from
pTRE cells and 3T3-E4 cells exposed to 1,000 ng/mL doxycyclin
were used for determining cell signaling.
Previous studies indicated that Ad36 up-regulates Ras/PI3K/
Glut4 pathway, and Glut1 and adiponectin – an insulin sensitizing
adipokine, to increase cellular glucose uptake [1–3]. In concor-
dance, E4orf1 expression also up-regulates the Ras/PI3K/Glut4
pathway, as indicated by significantly greater abundance of Ras, p-
AKT, Glut4, Glut1 and adiponectin (Figure 2 B–F). As described
below, we next determined if E4orf1 ‘activates’ Ras.
Experiment 3: E4orf1 interacts with Dlg1 and activates
Ras
Considering the significance of Ras in Ad36-induced glucose
uptake [2,3], we further investigated the interaction of E4orf1 with
Ras. Based on their systematic investigation of Ad 9 E4orf1
interaction with host proteins, Frese et al [10,11] proposed that
Ad9 E4orf1 binds to Dlg1 through its PBM. This binding triggers
the resulting complex to translocate to the plasma membrane to
promote Ras-mediated PI3K activation, for which the PBM
region of Ad9 E4orf1 is necessary. Modeled on this information,
Experiment 3 determined if Ad36 E4orf1 complexes with Dlg1
and whether E4orf1 activates Ras. The next experiment
(Experiment 4) determined if PBM of Ad36 E4orf1 is required
for Ras activation and glucose uptake.
Co-transfection of HEK293 cells with Dlg1 expressing plasmid
(GW1-CMV-HA-Dlg1) and with either plasmid expressing Ad36
E4orf1 (pcDNA-V5-Ad36 E4orf1) or null vector (pcDNA-V5-
DEST) showed that Dlg1 and E4orf1 co-immunoprecipitate
(Figure 3A). As expected, no E4orf1 precipitated in the IP protein
from the group cotransfected with Dlg1 and the null vector. The
whole cell lysate shows the HA-Dlg1 and V5-tagged E4orf1 bands,
confirming that transfection was successful. This result demon-
strated that Ad36 E4orf1 complexes with Dlg1 – similar to the
action of E4orf1 of Ad9, which binds to Dlg1 to mediate Ras
activation [10,11].
Next, we determined Ras activation. Ras has three main
isoforms, H-, K-, and N-Ras. After exposing 3T3-E4 cells with
1,000 ng/mL doxycycline for 24 hours, total Ras abundance was
greater (p=0.04), Figure 3 B(i & ii)) and total-Ras activation
(normalized to total Ras abundance) was about 6-fold higher in the
3T3-E4 cell line compared to the pTRE cell line treated similarly
(p=0.02; Figure 3B (i–iii)). H- and N-Ras isoforms, but not K-Ras
isoform were detectable by WB in these cells Figure 3B (i). N-Ras
or H-Ras abundance normalized to total Ras were 8 or 1.3 fold
greater, respectively (p=0.0001 and 0.007), for the E4orf1
expressing cells (data not shown). Interestingly, in these pre-
adipocytes, E4orf1 significantly activated only the H-Ras isoform
(p=0.01; Figure 3B (iv)) – the isoform that enhances glycemic
control in mice when transgenically overexpressed in adipose
tissue [15].
We next identified the region of E4orf1 protein that is required
to activate Ras and to up-regulate glucose uptake.
Experiment 4: E4orf1 requires its PBM for glucose uptake
and Ras activation
Ad9 E4orf1 requires its PBM to activate Ras and PI3K [10,11],
and Ad36 E4orf1 requires its PBM to up-regulate PI3K pathway
[9]. Hence, this experiment determined if the PBM region of Ad36
E4orf1 is critical for Ras activation and glucose uptake. E4orf1
transfection or constitutive expression significantly increased Ras
activation, or increased glucose uptake by nearly 5-fold,
respectively (Figure 4 A&B). Mutation in PBM of E4orf1
significantly attenuated the Ras activation or glucose uptake
induced by the intact E4orf1 protein (Figure 4 A&B). These data
identify the PBM region of Ad36 E4orf1 as an important site for
increasing cellular glucose uptake.
The results from experiment 1–4 suggest that Ad36 E4orf1
complexes with Dlg1 to mediate the activation of H-Ras to up-
regulate the downstream PI3K/Glut4 pathway and cellular
glucose uptake, and the PBM region of E4orf1 is necessary for
this action. Next, Experiment 5 identified the cell types responsive
to the effect of E4orf1 on glucose disposal.
Experiment 5: E4orf1 modulate glucose disposal in
preadipocytes, adipocytes, myoblasts or hepatocytes
Considering that the glucose uptake by adipose tissue and
skeletal muscle and glucose output by the liver contribute to
systemic glycemic control, we determined the effect of Ad36
Figure 1. Ad36 ‘requires’ E4orf1 for glucose uptake in 3T3-L1
cells. 3T3-L1 were transfected using lipofectamine with 100 pmol non-
targeting (NT) siRNA or E4orf1 siRNA. E4siRNA transfected cells were
immediately Mock infected or Ad36 infected (5 PFU/cell), and NT
transfected cells were infected with Ad36 as positive control. 2DG
uptake was determined and protein was harvested 2 days post
transfection/infection. Ad36 infected 3T3-L1 with NT siRNA transfection
had significantly greater glucose uptake than Mock-infected cells with
E4orf1 siRNA (p=0.007). When E4orf1 expression was knocked down
with E4orf1 siRNA, the effect of Ad36 on glucose uptake was inhibited.
doi:10.1371/journal.pone.0023394.g001
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23394Figure 2. E4orf1 is ‘sufficient’ to up-regulate cellular glucose uptake and to up-regulate the Ras/PI3k pathway. 3T3-E4(pTRE E4orf1)
and pTRE Null (pTRE) cell lines were treated with varying doses of Doxycycline for 24 h, and a dose-dependent 2DG uptake was determined. Protein
was also harvested from 3T3-E4 and pTRE Null treated with 1,000 ng/ml Doxycycline for 24 hours to determine signaling changes with E4orf1
expression. A) E4orf1 is sufficient to induce a dose-response increase in glucose uptake. 3T3-E4 and pTRE Null control cell lines were treated with 500,
750, or 1,000 ng/ml Doxycycline to induce different levels of E4orf1 expression, 2DG uptake was determined. Compared to pTRE, the E4orf1
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representing these tissues. Glucose disposal in 3T3-L1 preadipo-
cytes or adipocytes, C2C12 myoblasts or HepG2 hepatocytes
transfected with E4orf1 expressing plasmid (pcDNA-V5-Ad36
E4orf1) was compared with cells transfected with a null vector
(pcDNA-V5-DEST).
E4orf1 expression significantly increased basal 2DG uptake in
3T3-L1 preadipocytes, adipocytes and C2C12 myoblasts (Figure 5
A–C). In adipocytes, E4orf1 further increased insulin stimulated
2DG uptake (p=0.003). In preadipocytes and myoblasts, which
are not fully insulin responsive, E4orf1 did not enhance insulin
stimulated 2DG uptake.
Although multiple metabolic functions of the liver such as
glucose uptake, glycogen synthesis, glycogenolysis, contribute to
systemic glycemic control, hepatic glucose output is often
uncontrolled due to insulin resistance, and can be a key
contributor of high blood glucose in type 2 diabetes [16].
Therefore, we focused on determining the effect of E4orf1 on
glucose release by hepatocytes. E4orf1 transfection significantly
reduced glucose output by HepG2 cells under basal as well as
insulin stimulated conditions (p,0.000001 and ,0.001, respec-
tively; Figure 5D).
This experiment suggested that Ad36 E4orf1 may influence
glucose disposal by adipose tissue, skeletal muscle and liver.
Discussion
Ad36 infection improves glycemic control in chow-fed normo-
glycemic rats and mice [1,17] and in high fat fed hyperglycemic
mice [1]. Natural infection with Ad36 predicts better glycemic
control in normoglyemic and diabetic humans [1,2]. The virus
appears to exert its anti-hyperglyemic action by increasing glucose
uptake by preadipocytes, adipocytes, and myocytes, and by
reducing hepatic glucose output [1–3]. Ras/PI3K pathway
activation is required for Ad36-induced cellular glucose uptake
[2,3]. These findings are potentially highly significant for
developing new treatment approaches for type 2 diabetes and
insulin resistance. Particularly, the unique capability of Ad36 to
attenuate hyperglycemia despite a continued HF-diet and without
a reduction in visceral or subcutaneous adiposity [1] offers a
remarkable opportunity to creatively negate the hyperglycemic
effects of excess adiposity or dietary fat intake, without the need to
reduce it. However, for developing a therapeutic approach,
infection with a virus is impractical. Instead, a viral protein that
is responsible for the effect could provide a drug ligand or a target.
Here we show that E4orf1 is required to mediate the glucose
uptake induced by Ad36. Also, E4orf1 is sufficient to promote
glucose uptake in preadipocytes, adipocytes, and myoblasts, and to
reduce glucose output by hepatocytes.
Ad9 E4orf1, which is 96% homologous to Ad36 E4orf1,
mediates Ras activation by complexing with Dlg1 via its PBM
[10], which also appears to be the case with Ad36 E4orf1. Ad36
E4orf1 activates Ras and PI3K, the two main signaling
components required for Ad36 infection-induced glucose disposal
[2,3]. Ad36 E4orf1 requires its PBM for activating Ras and for up-
regulating glucose uptake. Specifically, Ad36 E4orf1 increases the
relative abundance and activation of H-Ras isoform.
Conventionally, insulin signaling for glucose disposal could be
divided in proximal signaling (the binding of insulin to its receptor
followed by the activation of insulin receptor substrates (IRS)1 and
IRS 2), and the distal signaling, which includes the activation of
PI3K pathway by IRS1 and IRS2, which leads to glucose
transporter mediated glucose disposal [1]. E4orf1 appears to
activate Ras, to induce the distal insulin signaling pathway. Ras,
an important GTP binding protein [18],[19], has been recognized
to induce PI3K/AKT pathway[20], or mimic insulin action on
glucose transporters Glut4 and Glut1 [21,22]. In a mouse model,
transgenic overexpression of H-Ras in adipose tissue increased
insulin sensitivity, and up-regulated adipose tissue Glut4 and Glut1
and glucose uptake even in absence of insulin [15]. Ras-induced
glucose disposal was ignored since it plays a negligible role in
insulin-stimulated glucose uptake [23–25]. Conversely, Ras/PI3K
pathway may be very valuable as an alternate pathway to promote
cellular glucose disposal, if insulin signaling is impaired. In the
absence of functional insulin signaling as in type 2 diabetes or
obesity [26–32], an agent such as E4orf1 that up-regulates insulin
independent glucose disposal through Ras activation may be
valuable. Very recently, Ras seems to re-attract attention for its
insulin-independent effects on glucose metabolism [33]. Future
experiments that knockdown Ras will determine if, like Ad36, its
E4orf1 protein also ‘requires’ Ras for promoting glucose disposal.
These data provide important information needed to design
ligands and therapeutic targets for improving glycemic control.
Although Ras is known as an oncogene, its activation alone is
not sufficient to induce tumor formation. For instance, dysregu-
lated focal adhesion kinase is necessary for Ras activation to result
in cell transformation [34]. In addition, transgenic over expression
of H-Ras in adipose tissue, the specific isoform activated by
E4orf1, does not cause tumor formation [15]. Although Ad36 up-
regulates the Ras/PI3K pathway, in several experiments lasting up
to 7 months, Ad36 infected animals did not develop tumors
[13,14,17,35]. Lastly, both Ad36 infection and E4orf1 transfection
are unable to induce anchorage independent growth, a marker of
cell transformation (unpublished data). Therefore, we hypothesize
that E4orf1 is not likely to be oncogenic, although this should be
tested more thoroughly in vivo.
E4orf1 modulated glucose disposal in pre-adipocytes, adipocytes
and, myoblasts indicate that E4orf1 may increase glucose disposal
in adipose tissue and skeletal muscle, both important tissues for
glucose clearance in vivo. Another physiologically relevant effect of
E4orf1 is the reduction of glucose output from HepG2
hepatocytes. In the insulin resistant condition, postprandial
glucose output from the liver is often uninhibited, contributing
to hyperglycemia [16]. Uncontrolled hepatic glucose output is one
of the first signs of type 2 diabetes. E4orf1, however, may be able
to diminish this hepatic source of blood glucose. Adiponectin - a
key insulin sensitizer secreted by adipocytes [36], is a controller of
hepatic glucose output [37,38]. In a previous study, we had
expressing cell had significantly greater glucose uptake when treated with 750 and 1,000 ng/ml Doxycycline (p *=0.007 and **=2.6610
27,
respectively). B) Ras WB and densitometry normalized to b-actin for 3T3-E4 and pTRE Null treated with 1,000 ng/ml Doxycycline for 24 hours. Ras
expression was significantly higher in the 3T3-E4 cell line (p=0.05). C) p-AKT and AKT WB and densitometry expressed as ratio of p-AKT to total AKT
in 3T3-E4 and pTRE Null treated with 1,000 ng/ml Doxycycline for 24 hours. p-AKT is significantly higher in the 3T3-E4 cell line (p=3.54*10
25). D)
Glut4 WB and densitometry normalized to b-actin for 3T3-E4 and pTRE Null treated with 1,000 ng/ml Doxycycline for 24 hours. Glut4 expression was
significantly higher in the 3T3-E4 cell line (p=0.05). E) Glut1 WB and densitometry normalized to b-actin for 3T3-E4 and pTRE Null treated with
1,000 ng/ml Doxycycline for 24 hours. Glut1 expression was significantly higher in the 3T3-E4 cell line (p=0.01). F) Adiponectin WB and densitometry
normalized to b-actin for 3T3-E4 and pTRE Null treated with 1,000 ng/ml Doxycycline for 24 hours. Adiponectin expression is significantly higher in
the 3T3-E4 cell line (p=0.006).
doi:10.1371/journal.pone.0023394.g002
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23394Figure 3. E4orf1 interacts with Dlg1 and activates Ras. HEK293 were co-transfected with GW1-CMV-HA-Dlg1 and either pcDNA-V5-Ad36
E4orf1 or a control plasmid (pcDNA-V5-DEST), and a pull down for HA was conducted and loaded to SDS-PAGE. WB were probed with V5 antibody to
detect Dlg1 and E4orf1 interaction. Also, 3T3-E4 and pTRE Null cell lines were treated with 1,000 ng/ml Doxycycline, and a Ras activation assay was
conducted. Following pull down, activated slurry and 6% of the whole cell lysate were loaded to SDS-PAGE and probed with total Ras antibodies, or
H-, N-, or K-Ras specific antibodies. Blots were also probed with b-actin, and densitometry was expressed as ratio of activated Ras to normalized total
Ras. A) WB show HA-Dlg1 and V5E4orf1 in the same complex after IP, indicating the binding of Ad36 E4orf1 with Dlg1. WB also shows the presence of
Dlg1 in the whole cell lysate (WCL). As expected, V5-E4orf1 is absent in pcDNA-V5-DEST group after IP for HA-Dlg1. B. (i) WB for total, H-, and N-Ras
activation. T=total (6% WCL) and A=Activated slurry. (ii) Total Ras abundance normalized to b-actin was significantly more in 3T3-E4 compared to
pTRE Null vector cell line (p=0.04). (iii)Total Ras activation densitometry, expressed as ratio of activated to normalized total Ras. Total Ras activation
was significantly greater in 3T3-E4 compared to pTRE Null (p=0.01). (iv) H-ras activation densitometry, expressed as ratio of activated H-Ras to
normalized total H-Ras. H-Ras activation was significantly more in 3T3-E4 compared to pTRE Null (p=0.01).
doi:10.1371/journal.pone.0023394.g003
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which then mediates the reduction in hepatic glucose output in
Ad36 infected mice [39]. The current study indicates that E4orf1
increases adiponectin expression in adipocytes, which may
secondarily influence hepatic metabolism. In addition, E4orf1
may directly effect glucose output by hepatocytes. A possible direct
effect on the liver is also supported by our previous finding that
E4orf1 mRNA expression in the livers of Ad36 infected mice
positively correlates with their glycemic improvement [39]. These
in vitro studies indicate that Ad36 E4orf1 may improve glycemic
control in vivo through adipose tissue, skeletal muscle, and liver- the
three main tissues involved in glucose homeostasis.
The in vivo glucose uptake induced by Ad36 is not uncontrolled,
as evident from a reduction in circulating glucose and insulin levels
observed in Ad36 infected mice, without inducing hypoglycemia
[39]. In vivo, Ad36 appears to reduce insulin required to maintain
glycemic control, indicating an ‘insulin sparing effect’ of the virus
[39]. E4orf1 may share this insulin sparing effect of Ad36. In
presence of insulin, E4orf1 induced glucose uptake in adipocytes
was significantly greater, but not additive.
Figure 4. E4orf1 requires its PBM for glucose uptake and Ras activation. 3T3-L1 cells were transfected with V-5 tagged plasmids expressing
E4orf1 (pcDNA-V5-AD36-E4orf1), mutant E4orf1 (pcDNA-V5- AD36-E4ORF1DPBM) or a null vector (pcDNA-V5-DEST) and a Ras activation assay was
conducted the next day. The activated slurry and 3% of whole cell lystate was loaded to SDS-PAGE and probed for Ras. Also 3T3-L1 cells that
constitutively express Ad36 E4orf1, a mutated E4orf1 (deleted PBM; DPBM) or Null vector were plated in 12 well plates and a 2DG uptake assay was
conducted the following day. A) WB for Ras activation assay: pcDNA-V5-AD36-E4orf1 activates Ras (p=0.04), whereas the Null vector (pcDNA-V5-
DEST) does not. pcDNA-V5- AD36-E4ORF1DPBM did not activate Ras, suggesting E4orf1 depends on its PBM region for Ras activation. Densitometry
expressed as ratio of activated Ras to normalized total Ras from 3% WCL WB. B) 2DG uptake in constitutive expressing Ad36 E4orf1, a mutated E4orf1
(deleted PBM; DPBM) or Null vector normalized to protein: E4orf1 increased glucose uptake compared to Null vector (p=0.008), and there was no
difference in glucose uptake when the PBM region of E4orf1 is mutated.
doi:10.1371/journal.pone.0023394.g004
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disposal has additional significance. Most of the currently available
anti-diabetic agents are either mimetics, sensitizers, or secreta-
gogues of insulin, which employ insulin signaling pathway for their
action. However, insulin resistant states such as obesity or diabetes
are often associated with impaired insulin signaling [26–32], which
may limit the efficacy of such drugs. Therefore, the potential of
E4orf1 to up-regulate glucose disposal without insulin stimulation
may be valuable for developing more effective anti-diabetic drugs.
We previously reported that in animal models, Ad36 is
adipogenic [13,14,35] and yet, it improves systemic glycemic
control [1,17] . In humans, natural Ad36 infection is associated
with obesity [40–44], as well as better glycemic control [1] and
lower hepatic steatosis [45] – a marker of insulin resistance. In vitro
studies show that Ad36 E4orf1 is necessary and sufficient to induce
adipogenesis [9]. Taken together, these data suggest that Ad36
E4orf1 protein induces adipogenesis as well as improves glycemic
control – an effect that is reminiscent of the action of anti-diabetic
agents Thiazolidinediones (TZDs) [46]. However, our very recent
data show that adipogenic effect of Ad36 could be successfully
uncoupled from its effect on glucose disposal (unpublished data).
Given the undesirable role of excess adiposity in glycemic control,
these findings increase the potential significance of anti-hypergly-
cemic action of Ad36. While it is likely that the adipogenic effect of
E4orf1 could also be uncoupled from its effect on glucose disposal,
it remains unknown at this time.
In conclusion, Ad36 E4orf1 protein enhances glucose disposal
in cell types from key tissues involved in glucose homeostasis.
Additional studies are needed to further elucidate the molecular
interactions of E4orf1 and to determine its effect on glycemic
control in vivo. Particularly, similar to the action of Ad36, if E4orf1
improves glycemic control without reducing dietary fat intake or
body fat, and independent of proximal insulin signaling, the
protein would be highly valuable to develop novel anti-diabetic
agents that mimic its action.
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